Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A11 | P48066 | 4/20 | 0.46 |
| ▸ | SLC6A1 | P30531 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | SLC6A12 | P48065 | 1/20 | 0.41 |
| ▸ | SLC6A13 | Q9NSD5 | 1/20 | 0.41 |
| ▸ | KIF11 | P52732 | 5/20 | 0.40 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27013149 | 0.88 | SLC6A11 (0.44) | SLC6A11SLC6A1KMT2AMEN1TP53 | |
| SCHEMBL8655117 | 0.88 | SLC6A11 (0.44) | SLC6A11SLC6A1KMT2AMEN1TP53 | |
| SCHEMBL8388886 | 0.85 | SLC6A11 (0.44) | SLC6A11SLC6A1KMT2AMEN1TP53 | |
| SCHEMBL8659005 | 0.85 | SLC6A11 (0.45) | SLC6A11SLC6A1KMT2AMEN1TP53 | |
| SCHEMBL9305514 | 0.85 | SLC6A11 (0.43) | SLC6A11SLC6A1KMT2AMEN1TP53 | |
| SCHEMBL9305860 | 0.83 | SLC6A11 (0.41) | SLC6A11SLC6A1KMT2AMEN1TP53 | |
| SCHEMBL2490410 | 0.83 | SLC6A11 (0.50) | SLC6A11SLC6A1KMT2AMEN1TP53 | |
| SCHEMBL992028 | 0.83 | SLC6A11 (0.50) | SLC6A11SLC6A1KMT2AMEN1TP53 | |
| SCHEMBL21449650 | 0.81 | SLC6A11 (0.40) | SLC6A11SLC6A1KMT2AMEN1TP53 | |
| SCHEMBL21449652 | 0.81 | SLC6A11 (0.40) | SLC6A11SLC6A1KMT2AMEN1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240254149-A1 | Chemical Phosphorylation Reagents, Preparation, and Their Uses | OLIX US, INC. | 2024-08-01 | — | — | US | disclosed |
| EP-4341270-A1 | CHEMICAL PHOSPHORYLATION REAGENTS, PREPARATION, AND THEIR USES | Olix US, Inc. (US) | 2024-03-27 | — | — | EP | disclosed |
| CN-117580848-A | Chemical phosphorylating reagent, preparation and use thereof | 奥利克斯美国公司 | 2024-02-20 | — | — | CN | disclosed |
| WO-2022246196-A1 | CHEMICAL PHOSPHORYLATION REAGENTS, PREPARATION, AND THEIR USES | OLIX US, INC. (US) | 2022-11-24 | — | — | WO | disclosed |
| EP-0816368-B1 | Chemical phoshorylation of oligonucleotides and reactants used therefor | GLEN RES CORP (US) | 2003-01-08 | — | — | EP | disclosed |
| EP-0804414-A4 | COMPLEMENTARY DNA AND TOXINS | SLOAN KETTERING INST CANCER (US) | 2000-04-12 | — | — | EP | disclosed |
| US-5959090-A | FORMING PHOSPHORAMIDITE COMPOUNDS FROM PHOSPHORYLATION | GLEN RESEARCH CORPORATION (US) | 1999-09-28 | — | — | US | disclosed |
| US-5807837-A | ADMINISTERING TO TREAT HIV INFECTIONS TO INHIBIT THE REPLICATION OF FOREIGN NUCLEIC ACIDS IN A NORMAL CELL | SANKYO COMPANY, LIMITED (JP) | 1998-09-15 | — | — | US | disclosed |
| EP-0816368-A1 | Chemical phoshorylation of oligonucleotides and reactants used therefor | Glen Research Corporation (US) | 1998-01-07 | — | — | EP | disclosed |
| EP-0804414-A1 | COMPLEMENTARY DNA AND TOXINS | Sloan-Kettering Institute For Cancer Research (US) | 1997-11-05 | — | — | EP | disclosed |
| US-5674856-A | TREATMENT AND PROPHYLAXIS OF VIRAL INFECTIONS, INCLUDING AIDS AND TUMORS | SANKYO COMPANY, LIMITED (JP) | 1997-10-07 | — | — | US | disclosed |
| US-5652350-A | Complementary DNA and toxins | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 1997-07-29 | — | — | US | disclosed |
| EP-0611075-B1 | Modified oligodeoxyribonucleotides, their preparation and their therapeutic use | SANKYO CO (JP) | 1996-12-18 | — | — | EP | disclosed |
| WO-1995031434-A1 | COMPLEMENTARY DNA AND TOXINS | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 1995-11-23 | — | — | WO | disclosed |
| EP-0611075-A1 | Modified oligodeoxyribonucleotides, their preparation and their therapeutic use | SANKYO COMPANY LIMITED (JP) | 1994-08-17 | — | — | EP | disclosed |
| US-5332845-A | In DNA synthesis | CHIRON CORPORATION (US) | 1994-07-26 | — | — | US | disclosed |
| US-5256549-A | Biosynthesis using blocked monomers; followed by enzymatic hydrolysis | CHIRON CORPORATION (US) | 1993-10-26 | — | — | US | disclosed |
| US-5252760-A | Method of using colored phosphorylating reagents | CHIRON CORPORATION (US) | 1993-10-12 | — | — | US | disclosed |
| EP-0304215-A2 | Phosphorylating reagents and method of using the same | CHIRON CORPORATION (US) | 1989-02-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240254149-A1 | Chemical Phosphorylation Reagents, Preparation, and Their Uses | PTMS, PPP4C, CHAMP1 | SLC6A11 4570/4885SLC6A1 4606/4885KMT2A 2135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.